Last update June 10, 2018
Very High Risk
Non-steroidal anti-estrogen with an estrogen antagonist action by binding to the estrogen receptor. Similar action to clomiphene.
Indicated in breast cancer after remission in order to prevent recurrence.
Oral administration once or twice a day for 5 years.
It has also been used in combination with clomiphene to induce ovulation (Suginami 1993).
Since the last update date we have not found published data on its excretion in breastmilk.
Its high binding to plasma proteins would hinder transfer to breastmilk, but high pKa and its long half-life make its transfer to breastmilk likely.
It inhibits breastfeeding in the immediate postpartum (Masala 1978, Shaaban 1975), possibly due to decreased prolactin levels (Jordan 1991).
Until there is more data about this product in relation to breastfeeding, scientific associations and expert authors strongly advise against breastfeeding while taking tamoxifen because of the risk of interfering with the infant's estrogen balance (Hale 2017 p.906, Pistilli 2013, WHO 2002, Helewa 2002).
We do not have alternatives for C26 H29 NO.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2012 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM